# Clinical Utility of TRBC1 Addition in Multiparametric Flow Cytometry for T Cell Lymphoma Diagnosis

## TL;DR

This paper shows how adding the TRBC1 antibody improves T cell lymphoma diagnosis using flow cytometry.

## Contribution

The study demonstrates the clinical utility of TRBC1 in identifying T cell lymphomas through multi-parametric flow cytometry.

## Key findings

- TRBC1 antibody helped exclude reactive lymphoproliferations in one case.
- TRBC1 conclusively identified Sezary syndrome cells in another case.
- TRBC1 combined with multi-parametric staining improves T cell immunophenotyping.

## Abstract

Diagnosis of T cell lymphoproliferative disorders requires one or multiple immunophenotypic aberrations, histological tissue structure or composition modifications, and T cell clonality demonstration. Here, we present two T cell lymphoma cases, where TCR clonality was evaluated using the TRBC1 monoclonal antibody combined with a multi-parametric staining for an in-depth immunophenotype of physiological and pathological T cell populations. In the first case, this monoclonal antibody allowed exclusion of reactive lymphoproliferations, while in the second case, it was conclusive for identification of Sezary syndrome cells. We added evidence on clinical utility of TRBC1 antibody (JOVI-1) to disclose monotypic T-cell populations, and TCR clonality evaluated by TRBC1 monoclonal antibody can be efficiently combined with a multi-parametric staining for an in-depth immunophenotype, with high versability of this monoclonal antibody in multi-parametric flow cytometry panel.